Replies to post #17437 on Oncolix Inc. (fka ONCX)

[BLight1911]

Redmans?

Redmanz?

Redmand?

Redmant?

Redmank?

IMO?

[reaper247]

LOL, OK laraz. Lets go point by point.

…the PPS was artificially inflated to .19 to allow him to sell shares to note takers?

Nonsense. In early 2017 when ONCX ran roughly 1000% not once, but twice ,there were no notes being converted. Notes werent issued until Nov.2017, when the PPS was about where it is now.

To claim that ONCX notes caused the erosion of the PPS from .19 is nonsense. It was retail trading. Anyone can verify for themselves.

You will not publically disclose who produced Prolanta in current clinical trials and you won't publically announce even 1 single patient was dosed in the current phase?

First off, Biovectra is a subsidiary Mallinckrodt Pharmaceuticals (NYSE: MNK,) who is the producer of Prolanta.

The former president of BioVectra proudly serves on the ONCX BOD and Mallinckrodt Pharmaceuticals holds ONCX stock through that subsidiary.

Second, the S-1A filed with the SEC 4/18/2018 clearly shows your opinion to be wrong.

"Our initial commercial focus is the development of Prolanta™ for the treatment of ovarian cancer. We have commenced a Phase 1 clinical trial after receiving clearance from the FDA. We completed the first dosing group of 3 subjects in the Phase I clinical trial, with no evidence of serious adverse events or dose-limiting toxicities".

This is a disgrace, almost 900 days in clinical trials without anything?

That is also wrong. Clearly the initial results were positive as stated numerous times through SEC filings and corporate presentations.

These are FDA clinical trials BTW.

The second round of dosing is ongoing. How anyone can expect a statement on the results of the second group, before they are completed is beyond me.

Its silly.

Hope that helps.

IMO and FWIW.